AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $4.37 million. The enterprise value is -$905,509.
| Market Cap | 4.37M |
| Enterprise Value | -905,509 |
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 30.44 million shares outstanding. The number of shares has increased by 1,256.22% in one year.
| Current Share Class | 30.44M |
| Shares Outstanding | 30.44M |
| Shares Change (YoY) | +1,256.22% |
| Shares Change (QoQ) | +89.82% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 3.95% |
| Float | 27.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.71 |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.75 |
| Quick Ratio | 2.60 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.27 |
Financial Efficiency
Return on equity (ROE) is -2,828.63% and return on invested capital (ROIC) is -290.73%.
| Return on Equity (ROE) | -2,828.63% |
| Return on Assets (ROA) | -95.51% |
| Return on Invested Capital (ROIC) | -290.73% |
| Return on Capital Employed (ROCE) | -164.54% |
| Weighted Average Cost of Capital (WACC) | 18.77% |
| Revenue Per Employee | $4,333 |
| Profits Per Employee | -$672,810 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.62% in the last 52 weeks. The beta is 1.31, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -90.62% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 36.36 |
| Average Volume (20 Days) | 522,100 |
Short Selling Information
The latest short interest is 1.00 million, so 3.29% of the outstanding shares have been sold short.
| Short Interest | 1.00M |
| Short Previous Month | 1.41M |
| Short % of Shares Out | 3.29% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 1.70 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $91,000 and -$14.13 million in losses. Loss per share was -$1.24.
| Revenue | 91,000 |
| Gross Profit | 35,000 |
| Operating Income | -11.65M |
| Pretax Income | -14.13M |
| Net Income | -14.13M |
| EBITDA | -11.15M |
| EBIT | -11.65M |
| Loss Per Share | -$1.24 |
Balance Sheet
The company has $6.95 million in cash and $1.67 million in debt, with a net cash position of $5.28 million or $0.17 per share.
| Cash & Cash Equivalents | 6.95M |
| Total Debt | 1.67M |
| Net Cash | 5.28M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 7.08M |
| Book Value Per Share | 0.18 |
| Working Capital | 4.66M |
Cash Flow
| Operating Cash Flow | -12.23M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 503,000 |
| Net Borrowing | 1.68M |
| Free Cash Flow | -12.23M |
| FCF Per Share | -$0.40 |
Margins
| Gross Margin | 38.46% |
| Operating Margin | -12,800.00% |
| Pretax Margin | -15,526.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,256.22% |
| Shareholder Yield | -1,256.22% |
| Earnings Yield | -864.45% |
| FCF Yield | -270.27% |
Analyst Forecast
The average price target for AIM ImmunoTech is $4.25, which is 2,859.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.25 |
| Price Target Difference | 2,859.61% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001:1.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |